Earnings Preview For Design Therapeutics
Portfolio Pulse from Benzinga Insights
Design Therapeutics (NASDAQ:DSGN) is expected to report a Q4 EPS of $-0.31 on 2024-03-19. Analysts and investors will be looking for positive guidance beyond the earnings beat or miss. The company's past earnings performance shows a mixed impact on its stock price, with the last quarter's beat resulting in an 11.71% share price increase.
March 18, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Design Therapeutics is anticipated to announce a Q4 EPS of $-0.31. Positive guidance could significantly influence its stock price, as seen in the past with an 11.71% increase following last quarter's earnings beat.
Given Design Therapeutics' history of stock price movements post-earnings announcements, especially with positive surprises and guidance, there's a strong likelihood of a positive short-term impact on its stock price if it beats the EPS estimate again and provides optimistic future guidance.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100